SPICA

SPICA™ is an AI-powered novelty assessment tool developed by Standigm, designed to support drug discovery teams in evaluating the patent novelty of new molecular structures generated through AI-driven synthesis. By delivering rapid and precise novelty evaluations, SPICA™ helps researchers and medicinal chemists determine whether their novel compounds have a clear path toward patent protection.

As an exclusive tool within Standigm's AI drug R&D platform, SPICA™ serves as a strategic partner for organisations seeking to accelerate and de-risk the early stages of drug discovery by ensuring that AI-generated molecules are assessed for intellectual property viability before significant resources are invested.

Core Capabilities

• Swiftly computes novelty prospects across a vast array of new molecular structures produced by AI synthesis pipelines
• Delivers rapid, precise evaluations of compound novelty to support patent strategy decisions
• Provides AI-driven novelty prediction to help identify which compounds are most likely to be protectable
• Functions as an integrated assessment layer within AI-powered drug discovery workflows

Key Benefits

• Accelerates the novelty screening process for large libraries of AI-generated compounds
• Reduces uncertainty around intellectual property positioning at the early discovery stage
• Enables research teams to prioritise compounds with stronger novelty profiles for further development
• Supports strategic decision-making by providing clear, data-driven novelty assessments

SPICA™ is offered by Standigm, a company focused on AI for new drug R&D. A demo and whitepaper are available for teams wishing to explore the tool's capabilities in greater depth.